New antibody trial aims to tame Sjögren's symptoms
NCT ID NCT07375524
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests an experimental drug called ESG206 in 40 adults with primary Sjögren's syndrome, an autoimmune disease causing dry eyes and mouth. The drug targets a protein to reduce immune system attacks on the body. Researchers will compare high and low doses against a placebo to see if it safely controls disease activity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ESG206 (a monoclonal antibody targeting BAFF-R)
What this could lead to
If successful, this could lead to a new treatment option that reduces disease activity and improves symptoms for people with Sjögren's syndrome.
What could go wrong
This is an early Phase 2 trial with only 40 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SJÖGREN SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Jining Medical University
Jining, Shandong, China
-
Affiliated Hospital of North Sichuan Medical College
Nanchong, Sichuan, China
-
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
-
Changde First People's Hospital
Changde, Hunan, China
-
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
-
Hebei Petro China Central Hospital
Langfang, Hebei, China
-
Huzhou Third People's Hospital
Huzhou, Zhejiang, China
-
Jinhua Municipal Central Hospital
Jinhua, Zhejiang, China
-
Peking University Shougang Hospital
Beijing, Beijing Municipality, China
-
Pingxiang People's Hospital
Pingxiang, Jiangxi, China
-
Qilu Hospital of Shandong University
Jinan, Shandong, China
-
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
-
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
-
The Second Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China
-
Wenzhou People's Hospital
Wenzhou, Zhejiang, China
-
Xiangya Hospital of Central South University
Changsha, Hunan, China
-
Xuzhou Central Hospital
Xuzhou, Jiangsu, China
-
Zaozhuang Municipal Hospital
Zaozhuang, Shandong, China
-
Zhuzhou Central Hospital
Zhuzhou, Hunan, China
-
the Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China